Overall survival (OS) analysis revealed that RBMX was a protective factor in patients suffering from cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), KIRC, rectum adenocarcinoma (READ), THYM, UCS, and uveal melanoma (UVM). This evidence concerns the gene RBMX and cervical squamous cell carcinoma.